---
title: "TRex Bio drops 9% as IPO prices at low end of range"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302913651.md"
description: "TRex Bio fell 8.97% to $14.11 after completing its IPO at $14 a share, raising $117 million."
datetime: "2026-10-23T17:24:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302913651.md)
  - [en](https://longbridge.com/en/news/302913651.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302913651.md)
generator: "portal-rs"
---

# TRex Bio drops 9% as IPO prices at low end of range

TRex Bio (TRXB.US) fell nearly **9%** during regular trading to **$14.11**.

The company completed its initial public offering at **$14** per share, the low end of its marketed range of $14 to $16, raising **$117 million**.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [TRXB.US](https://longbridge.com/en/quote/TRXB.US.md)

## Related News & Research

- [TRXB’s TRB-061 Drives Analyst Confidence as the $20 Price Target Remains Unchanged](https://longbridge.com/en/news/305821317.md)
- [Major Investor Makes Bold New Move into TRex Bio Stock](https://longbridge.com/en/news/301782322.md)
- [Novo Nordisk Highlights Protective Bone Biomarkers For CagriSema And Pediatric BMI Drops](https://longbridge.com/en/news/305843862.md)
- [BUZZ-Street View: Nvidia's AI story intact despite uncertainty at top](https://longbridge.com/en/news/305945171.md)
- [INSTANT VIEW-Nvidia earnings beat estimates; attention turns to call](https://longbridge.com/en/news/305875718.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**